The authors tested the Braunwald classification for its predictive validity for underlying coronary conditions, clinical courses, and responses to treatment. A reliable definition and classification of unstable angina is needed to help physicians make correct diagnoses of patients' conditions and to appraise findings from clinical trials critically. Many clinical trials have been conducted, but it is difficult to compare the results because of different entry criteria. Of 113 consecutive patients admitted with unstable angina, 89 who had primary angina were studied. Braunwald's classification was applied at admission. The outcomes of interest during hospitalization were coronary angiographic findings, short-term prognoses, and the treatment selected. Multivariate analysis showed that the severity class expressed significant positive predictivity for coronary thrombi (adjusted odds ratio [OR], 6.53; 95% confidence interval [CI], 2.82 to 15.1) and progress to impending infarction (OR, 10.43; CI, 3.35 to 32.49). The treatment (OR, 0.02; CI, 0.004 to 0.08) and electrocardiographic (OR, 0.22; CI 0.10 to 0.49) classes showed independent negative predictivity for coronary vasospasm. The treatment (OR, 3.50; CI, 1.94 to 6.33) and electrocardiographic (odds ratio, 3.27; CI, 1.87 to 5.71) classes showed positive predictivity for the necessity for recanalization treatment with coronary angioplasty or bypass grafting. The Braunwald classification used at admission is highly predictive of underlying coronary conditions, progression to impending infarction, and the final selection of treatment. This classification should be considered in determining patient eligibility in clinical trials and studies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/000331979704800801 | DOI Listing |
J Cardiovasc Dev Dis
September 2024
Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua Medical School, 35121 Padova, Italy.
JAMA Cardiol
April 2024
Cardiovascular Medicine Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
NPJ Digit Med
October 2022
Division of Vascular and Endovascular Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
After creation of a new arteriovenous fistula (AVF), assessment of readiness for use is an important clinical task. Accurate prediction of successful use is challenging, and augmentation of the physical exam with ultrasound has become routine. Herein, we propose a point-of-care tool based on machine learning to enhance prediction of successful unassisted radiocephalic arteriovenous fistula (AVF) use.
View Article and Find Full Text PDFJ Card Fail
January 2023
Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address:
Objectives: To investigate risk factors and outcomes of cardiogenic shock complicating acute myocardial infarction (AMI-CS) in young patients with AMI.
Background: AMI-CS is associated with high morbidity and mortality rates. Data regarding AMI-CS in younger individuals are limited.
Eur J Heart Fail
October 2022
Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School Boston, Boston, MA, USA.
Aim: The win ratio can incorporate different types of outcomes and enhance statistical power, making it a useful method for analysing composite outcomes in cardiovascular trials. The application of this approach to the PARADISE-MI trial provides an additional perspective into understanding the effects of sacubitril/valsartan in patients with acute myocardial infarction.
Methods And Results: We conducted a post-hoc analysis of the PARADISE-MI trial, which randomly assigned patients with acute myocardial infarction complicated by a reduced left ventricular ejection fraction, pulmonary congestion, or both to receive either sacubitril/valsartan (97 mg of sacubitril and 103 mg of valsartan twice daily) or ramipril (5 mg twice daily) in addition to guideline-recommended therapy.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!